Abstract: The present invention relates to a non-invasive method for predicting the responsiveness of a human subject suffering from inflammatory disease to a treatment with a therapy against said inflammatory disease using brain imaging techniques. Furthermore, the present invention relates to a pharmaceutical composition comprising an active ingredient for the treatment of human subjects suffering from inflammatory disease and being identified as responders to therapy against the inflammatory disease according to the method of the invention. Preferably, this invention relates to a non-invasive method for predicting the responsiveness of a human subject suffering from rheumatoid arthritis to a treatment with TNF-antagonists comprising at least one step of brain imaging, preferably with an fMRI apparatus. The present invention shows that response to TNFi depends on the gestalt of brain activity in rheumatoid arthritis (RA) patients.

Abstract: There is provided a method of determining a transmission quality when receiving audio signals which are transmitted over a frequency-modulated path in analog form. For that purpose a frequency-modulated audio signal is received and IQ demodulation of the input signal is implemented. The I- and the Q-path of the demodulated baseband signal are subjected to analog/digital conversion. Alternatively the input signal can first be digitized and then subjected to IQ demodulation. A multiplicity of N samples is detected. The amount of the N samples is formed. A reference value is determined from the amount of the N samples. Each of the N samples is standardized to the reference value. A measurement in respect of the fluctuations in the standardized amounts is determined. The measurement in respect of the fluctuations indicates the quality of the transmission path.